These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30635947)

  • 41. Prion encephalopathies of animals and humans.
    Prusiner SB
    Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes.
    Wang X; Cui M; Zhao C; He L; Zhu D; Wang B; Du W
    Inorg Chem; 2014 May; 53(10):5044-54. PubMed ID: 24787240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation.
    Wang X; Zhu D; Zhao C; He L; Du W
    Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gerstmann-Sträussler-Scheinker disease.
    Liberski PP
    Adv Exp Med Biol; 2012; 724():128-37. PubMed ID: 22411239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of PrP in health and disease.
    Flechsig E; Weissmann C
    Curr Mol Med; 2004 Jun; 4(4):337-53. PubMed ID: 15354865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular uptake of the prion protein fragment PrP106-126 in vitro.
    McHattie SJ; Brown DR; Bird MM
    J Neurocytol; 1999 Feb; 28(2):149-59. PubMed ID: 10590514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular approaches to mechanisms of prion diseases.
    Bratosiewicz-Wasik J; Wasik TJ; Liberski PP
    Folia Neuropathol; 2004; 42 Suppl A():33-46. PubMed ID: 15449458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of prion peptide structure and aggregation in toxicity and membrane binding.
    Rymer DL; Good TA
    J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
    Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
    Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Properties and pathogenicity of prion-derived peptides.
    Vassallo N
    Protein Pept Lett; 2009; 16(3):230-8. PubMed ID: 19275735
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126.
    Kanapathipillai M; Ku SH; Girigoswami K; Park CB
    Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of prion-induced modifications in membrane transport properties: implications for signal transduction and neurotoxicity.
    Kourie JI
    Chem Biol Interact; 2001 Oct; 138(1):1-26. PubMed ID: 11640912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PrPSc-like prion protein peptide inhibits the function of cellular prion protein.
    Brown DR
    Biochem J; 2000 Dec; 352 Pt 2(Pt 2):511-8. PubMed ID: 11085945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of the JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by PrP106-126 and prion infection.
    Carimalo J; Cronier S; Petit G; Peyrin JM; Boukhtouche F; Arbez N; Lemaigre-Dubreuil Y; Brugg B; Miquel MC
    Eur J Neurosci; 2005 May; 21(9):2311-9. PubMed ID: 15932590
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel PRNP-P105S mutation associated with atypical prion disease and a rare PrPSc conformation.
    Tunnell E; Wollman R; Mallik S; Cortes CJ; Dearmond SJ; Mastrianni JA
    Neurology; 2008 Oct; 71(18):1431-8. PubMed ID: 18955686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aggregation/fibrillogenesis of recombinant human prion protein and Gerstmann-Sträussler-Scheinker disease peptides in the presence of metal ions.
    Ricchelli F; Buggio R; Drago D; Salmona M; Forloni G; Negro A; Tognon G; Zatta P
    Biochemistry; 2006 May; 45(21):6724-32. PubMed ID: 16716083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute Neurotoxicity Models of Prion Disease.
    T Islam AM; Adlard PA; Finkelstein DI; Lewis V; Biggi S; Biasini E; Collins SJ
    ACS Chem Neurosci; 2018 Mar; 9(3):431-445. PubMed ID: 29393619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathogenesis of prion diseases.
    Unterberger U; Voigtländer T; Budka H
    Acta Neuropathol; 2005 Jan; 109(1):32-48. PubMed ID: 15645262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biology and genetics of prion diseases.
    Prusiner SB
    Annu Rev Microbiol; 1994; 48():655-86. PubMed ID: 7826022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.